Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07079735 · ClinicalTrials.gov registry record · Phase 2
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
A Phase 2 study of Heart Transplant Failure and Rejection and Heart Transplant Infection, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT07079735 is a Phase 2 study of Heart Transplant Failure and Rejection and Heart Transplant Infection that is actively recruiting participants, run by Columbia University. The registered enrollment target is 150 participants, below the 181-participant average among 5 other Heart Transplant Failure and Rejection trials with a reported enrollment target (17% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07079735, a Phase 2 study of Heart Transplant Failure and Rejection and Heart Transplant Infection, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Conditions Studied
Interventions
- DRUG Letermovir
- DRUG Valganciclovir
Study Locations (2)
New York
- NYP-Weill Cornell - New York
- Columbia University/NYP Milstein Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-12 |
| Est. Completion | 2029-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07079735
The ClinicalTrials.gov registry entry for NCT07079735 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 5 other Heart Transplant Failure and Rejection trials with a reported enrollment target (17% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Heart Transplant Failure and Rejection appearing as the primary indexed condition, and to 2 interventions - of which Letermovir is the first listed.
NCT07079735 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07079735 about?
NCT07079735 is a clinical study titled "Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant". The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
What is the current status of trial NCT07079735?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-09-12. Estimated completion is 2029-01-17.
What conditions does trial NCT07079735 study?
This clinical trial studies the following conditions: Heart Transplant Failure and Rejection, Heart Transplant Infection, CMV Viremia.
What interventions are being tested in trial NCT07079735?
The interventions under investigation include: Letermovir (DRUG), Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT07079735?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07079735 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplant Failure and Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allograft Dysfunction in Heart Transplant
RECRUITING · Phase 4
-
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
ACTIVE NOT RECRUITING
-
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
ACTIVE NOT RECRUITING · NA
-
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
ACTIVE NOT RECRUITING · NA
-
Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
COMPLETED
Explore more on PlainTrial
Heart Transplant Failure and Rejection
All registered trials for this condition
Heart Transplant Infection
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.